Farallon Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Farallon Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Shares Change %	Capital Flow	Portfolio Weight	Portfolio Position
2025 Q2	$341M	Buy	6,172,006 +65,000	+1%	+$3.59M	1.47%	25
2025 Q1	$295M	Buy	6,107,006 +177,000	+3%	+$8.56M	1.46%	26
2024 Q4	$229M	Buy	5,930,006 +69,000	+1%	+$2.66M	1.02%	32
2024 Q3	$264M	Buy	5,861,006 +20,233	+0.3%	+$910K	1.16%	28
2024 Q2	$202M	Buy	5,840,773 +101,800	+2%	+$3.53M	0.87%	31
2024 Q1	$166M	Buy	5,738,973 +4,543	+0.1%	+$131K	0.71%	34
2023 Q4	$131M	Buy	5,734,430 +288,000	+5%	+$6.6M	0.6%	38
2023 Q3	$90.8M	Buy	5,446,430 +935,000	+21%	+$15.6M	0.42%	43
2023 Q2	$125M	Buy	4,511,430 +1,896,416	+73%	+$52.4M	0.63%	40
2023 Q1	$60.1M	Sell	2,615,014 -1,036,873	-28%	-$23.8M	0.33%	56
2022 Q4	$39.8M	Hold	3,651,887	–	–	0.24%	66
2022 Q3	$30.8M	Sell	3,651,887 -48,721	-1%	-$411K	0.17%	84
2022 Q2	$29.3M	Buy	3,700,608 +2,566,151	+226%	+$20.3M	0.16%	84
2022 Q1	$26.9M	Sell	1,134,457 -782,677	-41%	-$18.5M	0.13%	85
2021 Q4	$65.6M	Sell	1,917,134 -474,866	-20%	-$16.2M	0.33%	56
2021 Q3	$42.4M	Buy	2,392,000 +62,320	+3%	+$1.1M	0.2%	76
2021 Q2	$105M	Sell	2,329,680 -95,320	-4%	-$4.28M	0.43%	50
2021 Q1	$62.8M	Hold	2,425,000	–	–	0.31%	62
2020 Q4	$48.9M	Sell	2,425,000 -325,000	-12%	-$6.55M	0.29%	63
2020 Q3	$53.8M	Buy	2,750,000 +250,000	+10%	+$4.89M	0.37%	61
2020 Q2	$44.2M	Buy	2,500,000 +1,000,000	+67%	+$17.7M	0.35%	59
2020 Q1	$10.6M	Hold	1,500,000	–	–	0.09%	77
2019 Q4	$10.6M	Hold	1,500,000	–	–	0.07%	95
2019 Q3	$18M	Hold	1,500,000	–	–	0.14%	74
2019 Q2	$18.2M	Sell	1,500,000 -290,000	-16%	-$3.51M	0.12%	79
2019 Q1	$22.5M	Sell	1,790,000 -409,674	-19%	-$5.15M	0.17%	68
2018 Q4	$14.8M	Sell	2,199,674 -43,528	-2%	-$293K	0.11%	71
2018 Q3	$23.1M	Buy	2,243,202 +1,332,973	+146%	+$13.7M	0.14%	61
2018 Q2	$6.12M	Sell	910,229 -103,271	-10%	-$694K	0.04%	83
2018 Q1	$8.71M	Buy	1,013,500 +113,500	+13%	+$975K	0.06%	75
2017 Q4	$18.7M	Buy	+900,000	New	+$18.7M	0.15%	56